GSK launches US$2.5 billion savings drive to boost drug pipeline

GSK announced on July 28, 2026, a £1.9 billion (US$2.52 billion) cost-savings program aimed at funding the British drugmaker's late-stage clinical studies. The initiative is part of CEO Luke Miels' strategy to accelerate drug development and restore investor confidence. The program will involve significant cost reductions across the company to redirect resources toward its pipeline of experimental medicines. The announcement was made in London and reported by The Business Times Singapore.

First published Aug 4, 02:04 PM UTCUpdated Jul 28, 11:42 AM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 28, 11:42 AM UTCEditorial record as of Aug 4, 02:04 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

Opened from WirecurrentJul 28, 11:42 AM UTC

GSK launches US$2.5 billion savings drive to boost drug pipeline

Coverage sources

External reporting used to assemble this Story.

GSK launches US$2.5 billion savings drive to boost drug pipelineThe Business TimesRegionalJul 28, 11:42 AM UTC

Follow the context

London